AstraZeneca and Roche each entered collaborations to take on hospital infections.
As noted by PMLive, AstraZeneca’s collaboration with the Agency for Science, Technology and Research to attack gram-negative infections appears somewhat at odds with the drugmaker’s decision to scale back its infection R&D.
Roche announced Monday that it is pursuing antibiotic research with private drugmaker Polyphor, with which it will target pseudomonas aeruginosa, an infection which the companies say accounts for 10% of US hospital-acquired infections.
